U.S. Metals and Mining Stock News

NasdaqGS:HQY
NasdaqGS:HQYHealthcare

HealthEquity (HQY) Margin Expansion To 16.4% Tests Bearish Cost Narratives

HealthEquity (HQY) has wrapped up FY 2026 with fourth quarter revenue of US$334.6 million and basic EPS of US$0.58, backed by trailing twelve month revenue of about US$1.3 billion and EPS of US$2.50 alongside very large year over year earnings growth of 122.5%. Over recent periods the company has seen quarterly revenue move from US$300.4 million in Q3 FY 2025 to US$334.6 million in Q4 FY 2026, while basic EPS has shifted from US$0.07 to US$0.58, prompting investors to focus on how expanding...
NYSE:VAC
NYSE:VACHospitality

Did a New Sales Chief and Counsel Exit Just Shift Marriott Vacations Worldwide's (VAC) Investment Narrative?

Marriott Vacations Worldwide recently reshaped its leadership team, appointing industry veteran Tony Walker as Executive Vice President and Chief Sales and Marketing Officer while long-serving General Counsel James Hunter stepped down ahead of his planned retirement. This leadership transition brings in deep timeshare and experience-based sales expertise at a moment when the company is working through weak demand, competition, and operational challenges highlighted by recent analyst...
NYSE:MOH
NYSE:MOHHealthcare

Is Molina Healthcare (MOH) Offering Opportunity After Medicaid Contract Concerns And Strong DCF Upside

Wondering if Molina Healthcare at around US$143.96 is a bargain or a value trap? This article focuses squarely on what the current price actually says about the stock. The share price has moved 1.9% over the last week and 6.4% over the last month, but the year-to-date return of 19.3% and 1-year return of 54.6% decline give a very different context to where the stock sits today. Recent news coverage has centered on Molina Healthcare's position in the managed care space, including commentary...
NYSE:SMR
NYSE:SMRElectrical

Does NuScale Power (SMR) Share Price Still Match Its Long Term Nuclear Story?

Wondering whether NuScale Power's current share price still reflects the story you have in mind, or if the stock is now pricing in a very different future. NuScale shares recently closed at US$12.44, with returns of 3.4% over 7 days but a 13.1% decline over 30 days and a 23.7% decline year to date, alongside a 25.0% decline over the last year and gains of 40.4% over 3 years and 25.9% over 5 years. These mixed returns sit against a backdrop of ongoing attention on nuclear energy...
NYSE:CARR
NYSE:CARRBuilding

Carrier Global Backs Heat Geek To Tap European Heat Pump Growth

Carrier Global Ventures, the venture arm of NYSE:CARR, has invested in UK-based residential heat pump platform Heat Geek. The partnership is aimed at accelerating residential heat pump adoption across Europe. The move expands Carrier's presence in electrified heating and digital solutions for homeowners. For you as an investor, this connects directly to Carrier's core role in heating, ventilation and air conditioning, as well as its focus on climate technologies. Heat pumps are an important...
NYSE:GPC
NYSE:GPCRetail Distributors

Is Genuine Parts (GPC) Offering Value After The Recent 30% Share Price Slide

Wondering if Genuine Parts at around US$102.82 is offering real value right now, or if the recent share price moves are a warning sign you should pay attention to. Over the last week the stock has seen a 5.6% decline, with a 30.1% decline over 30 days and a 17.1% decline year to date, set against a 14.3% decline over 1 year and a modest 2.9% gain across 5 years. These moves sit against a backdrop where investors are reassessing auto and industrial parts distributors in general, focusing more...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Assessing Summit Therapeutics (SMMT) Valuation After Jefferies Downgrade And Mixed Quarter

Summit Therapeutics (SMMT) is back in focus after a Jefferies downgrade to Hold, tied to risks around four major 2026 clinical catalysts and a mixed fourth quarter 2025 earnings update. See our latest analysis for Summit Therapeutics. The Jefferies downgrade and mixed fourth quarter 2025 earnings update come after a year where the share price return is weak year to date at a 9.53% decline, despite a very large three year total shareholder return that indicates earlier buyers have already seen...
NasdaqGS:XP
NasdaqGS:XPCapital Markets

Is It Time To Revisit XP (XP) After Recent Share Price Pullback?

If you are wondering whether XP at US$19.03 still offers value or if the easy gains are behind it, the key is to look closely at what the current price actually implies. The stock has had mixed recent moves, with a 5.5% decline over the last 7 days and a 4.2% decline over the last 30 days, set against a 17.6% return year to date and 25.9% over the past year. These swings sit on top of a longer record that includes an 81.2% return over 3 years and a 44.7% decline over 5 years. This history...
NYSE:HE
NYSE:HEElectric Utilities

Is Hawaiian Electric Industries (HE) Attractive After Recent Rebound And Ongoing Regulatory Headlines

With Hawaiian Electric Industries trading at around US$14.49, this article explores whether the stock might represent a bargain or a value trap by walking through key aspects of the current valuation. The stock has returned 14.7% year to date and 31.6% over the last year, while 3 year and 5 year returns show declines of 60.5% and 62.1%. This contrast may leave you considering how to weigh recent momentum against longer term performance. Recent headlines around Hawaiian Electric Industries...
NasdaqGS:EA
NasdaqGS:EAEntertainment

Assessing Electronic Arts (EA) Valuation After A Period Of Steady Long Term Shareholder Returns

Electronic Arts stock snapshot after recent performance Electronic Arts (EA) shares recently closed at US$200.13, with a 1 day return close to flat and modest moves over the past week, month, and past 3 months that frame a relatively muted short term performance profile. See our latest analysis for Electronic Arts. While the short term share price return has been slightly negative year to date, the 1 year total shareholder return of 41.67% and 3 year total shareholder return of 76.82% point...
NasdaqCM:VFF
NasdaqCM:VFFFood

A Look At Village Farms International’s Valuation As Profitability Follows Higher Quarterly And Annual Sales

Why the latest earnings and buyback matter for Village Farms International (VFF) Village Farms International (NasdaqCM:VFF) has drawn fresh attention after reporting fourth quarter and full year 2025 results that show net income for both periods, alongside completion of a US$2.98 million share repurchase program. See our latest analysis for Village Farms International. Despite turning net income positive for both the quarter and full year and completing the US$2.98 million buyback, Village...
NYSE:MTB
NYSE:MTBBanks

M&T Bank Technology And Talent Push Versus Valuation Discount And Risks

M&T Bank (NYSE:MTB) CEO releases an annual letter highlighting investments in technology and talent as key priorities. The letter links these investments to the bank’s recent performance and outlines how they fit into long term plans. Management stresses a sustained focus on digital capabilities, data, and workforce development in a choppy economic climate. M&T Bank is a regional banking group with a focus on traditional lending, deposits, and related financial services, and it operates in...
NasdaqGS:FROG
NasdaqGS:FROGSoftware

Is JFrog (FROG) Priced Right After Strong Multi Year Share Price Performance

If you are wondering whether JFrog's current share price reflects its true worth, this breakdown will help you connect the recent numbers to what you are actually paying for the stock. At a last close of US$43.83, JFrog has returned 7.1% over the past week, while the 30 day and year to date returns of 15.2% and 26.4% respectively contrast with a 29.2% return over the past year and 127.7% over three years. Recent headlines have focused broadly on the software sector and investor interest in...
NYSE:TXT
NYSE:TXTAerospace & Defense

The Bull Case For Textron (TXT) Could Change Following New Global Public-Safety Helicopter Orders – Learn Why

Textron’s Bell unit recently secured orders from South Africa’s National Transmission Company for seven Bell 407GX helicopters and from the Pasadena Police Department for two Bell 505 helicopters, all designated for utility and public safety missions. These contracts highlight how Textron is extending the reach of its helicopter portfolio into both international infrastructure work and specialized municipal law‑enforcement operations. Next, we’ll examine how these new helicopter orders,...
NYSE:AVTR
NYSE:AVTRLife Sciences

Eversept Ups Avantor Stake As Revival Program And Valuation Draw Focus

Eversept Partners has made a significant institutional investment in Avantor (NYSE:AVTR), increasing its ownership stake in the company. The move comes as Avantor presses ahead with its Revival program, which is aimed at responding to prolonged organic revenue declines and restructuring efforts. These ownership changes and internal initiatives are drawing fresh attention to Avantor's potential direction and risk profile. Avantor supplies products and services to the life sciences and...
NYSE:HEI
NYSE:HEIAerospace & Defense

Is It Too Late To Consider HEICO (HEI) After The Recent Share Price Pullback?

Wondering if HEICO at around US$292.21 is still offering value, or if the best days are already priced in? This article focuses squarely on what you are paying versus what you might be getting. The share price sits near US$292.21 after a 4.6% decline over the past week and 12.1% over the last month, yet the stock has returned 12.1% over 1 year, 74.6% over 3 years and 140.9% over 5 years. Recent coverage has focused on HEICO as a key aerospace and defense name, with investors watching how...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

Nuvation Bio Cancer Data Update Tests Valuation Gap After Share Pullback

Nuvation Bio (NYSE:NUVB) presented nearly one additional year of follow up data from the TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) at the AACR Annual Meeting 2026. The new data focus on long term efficacy and safety in ROS1 positive non small cell lung cancer, including both treatment naïve and previously treated patients. This update builds on IBTROZI's existing FDA approval and adds fresh clinical detail that has not been reflected in recent coverage of the company. Nuvation...
NYSE:KR
NYSE:KRConsumer Retailing

Cold Case Rollout Tests Kroger’s Premium Ice Cream And Brand Strategy

Cold Case Ice Cream is expanding into more than 1,000 Kroger banner stores across the US. The rollout brings a trend-focused premium ice cream brand to a wide range of Kroger owned banners. The move underscores Kroger's focus on differentiated product assortments in the grocery aisle. For investors watching NYSE:KR, this large scale rollout highlights how Kroger is using branded partnerships to keep its frozen aisle fresh and relevant. The company operates a broad network of supermarket...
NasdaqGS:MU
NasdaqGS:MUSemiconductor

Is It Too Late To Consider Micron Technology (MU) After Its Surging Share Price?

For investors wondering whether Micron Technology at US$461.69 is priced for perfection or still offers value, this article walks through what the numbers indicate about the stock. The share price performance has been strong, with returns of 14.5% over 7 days, 12.2% over 30 days, 46.4% year to date, 355.4% over 1 year, around 7x over 3 years, and 454.1% over 5 years. These moves can change how investors think about both upside and risk. These moves are playing out against a backdrop where...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Assessing Gold.com (GOLD) Valuation After Board Changes And New Commodities Expertise

Gold.com (GOLD) drew investor attention after appointing Juan Sartori to its Board of Directors and announcing the retirement of longtime director Beverley Lepine, a governance shift linked to experience in commodities and alternative assets. See our latest analysis for Gold.com. The Board change comes as Gold.com trades at a share price of $47.89, with a 46.45% 90 day share price return and a 71.11% 1 year total shareholder return. This suggests recent momentum has been strong despite a...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

A Look At GeneDx Holdings (WGS) Valuation After Ark Buying And Zevra Genetic Testing Partnership

GeneDx Holdings (WGS) is back in focus after Ark Invest’s ETFs bought shares for seven straight trading days, alongside a new Niemann Pick disease type C genetic testing collaboration with Zevra Therapeutics. See our latest analysis for GeneDx Holdings. Despite Ark’s buying streak and the new Zevra partnership, GeneDx’s share price has been under pressure, with a 30 day share price return of a 16.25% decline and a year to date share price return of a 42.93% decline, while the three year total...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance

Recent performance snapshot EyePoint (EYPT) has drawn attention after mixed recent returns, with the share price up about 7% over the past month but showing a decline over the past 3 months and year to date. At a last close of US$13.90 and a market value of about US$1.12b, investors are weighing this performance against the company’s focus on retinal disease treatments and its developing product pipeline. See our latest analysis for EyePoint. That mix of a 7.42% 30 day share price return...
NYSE:MSGE
NYSE:MSGEEntertainment

A Look At Madison Square Garden Entertainment (MSGE) Valuation After The Appointment Of New Chief Legal Officer

Madison Square Garden Entertainment (MSGE) has drawn fresh investor attention after appointing Allen Lo as Executive Vice President and Chief Legal Officer, a move that more closely connects the live entertainment group to deep technology and media legal expertise. See our latest analysis for Madison Square Garden Entertainment. The appointment of Allen Lo comes at a time when MSGE’s share price has pulled back in the short term. The 1 month share price return shows an 8% decline, but the 90...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS?

In March 2026, Corvus Pharmaceuticals filed a universal shelf registration and expanded its at-the-market equity program with Jefferies to US$200 million, adding flexibility to issue common and preferred stock, debt, warrants and units to support ongoing operations. This expanded financing capacity sits alongside a sharp reduction in full-year 2025 net loss to US$15.28 million and continued clinical progress for lead candidate soquelitinib, together reshaping how investors may view the...